Published in Blood on March 01, 1988
Erythrocytes from young but not elderly donors can bind and degrade immune complex- and antibody-bound C3 in vitro. Clin Exp Immunol (1994) 0.78
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation. Proc Natl Acad Sci U S A (1977) 2.80
Membrane complement receptors specific for bound fragments of C3. Adv Immunol (1985) 2.80
Specificity of human lymphocyte complement receptors. J Exp Med (1975) 2.77
Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol (1981) 2.74
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 2.68
Human granulocyte generation of hydroxyl radical. J Exp Med (1978) 2.54
Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol (1996) 2.41
Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med (1982) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
Analysis of the different types of leukocyte membrane complement receptors and their interaction with the complement system. J Immunol Methods (1980) 2.17
p150/95, Third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody. Eur J Immunol (1985) 2.14
Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J Exp Med (1980) 1.96
Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest (1988) 1.92
Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody. Proc Natl Acad Sci U S A (1981) 1.86
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Membrane receptors of mouse leukocytes. II. Sequential expression of membrane receptors and phagocytic capacity during leukocyte differentiation. J Exp Med (1978) 1.69
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 1.64
The sequential appearance of Ia-like antigens and two different complement receptors during the maturation of human neutrophils. J Exp Med (1978) 1.56
Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation. J Immunol (1988) 1.56
Autoimmune neutropenia. Blood (1993) 1.52
Mnemonic device for criteria for borderline personality disorder. Am J Psychiatry (1989) 1.38
Differential diagnosis of schizophrenia and multiple personality disorder. Am J Psychiatry (1990) 1.38
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Human megakaryocytes. I. Characterization of the membrane and cytoplasmic components of isolated marrow megakaryocytes. J Exp Med (1979) 1.31
Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol (1994) 1.30
Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest (1973) 1.29
Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol (1993) 1.26
Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria. J Clin Invest (1974) 1.24
Identification of human lymphocyte subpopulations by surface marker analysis. Blood (1979) 1.22
Characterization of the lymphocyte membrane receptor for factor H (beta 1H-globulin) with an antibody to anti-factor H idiotype. J Exp Med (1982) 1.21
Chlorpropamide-induced immune hemolytic anemia. N Engl J Med (1970) 1.20
Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis. J Clin Invest (1978) 1.18
Assay for the two different types of lymphocyte complement receptors. Scand J Immunol (1976) 1.18
Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia (2004) 1.17
Structure and function of membrane complement receptors. Summary. Fed Proc (1982) 1.15
Pulmonary and hepatic complications of methotrexate therapy of psoriasis. JAMA (1971) 1.14
Surface markers of human eosinophils. Blood (1976) 1.13
Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology (2000) 1.12
Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome. J Clin Invest (1973) 1.10
Comparison of various tests for Fc receptors on different human lymphocyte sub populations. Clin Exp Immunol (1979) 1.10
The lysis of paroxysmal nocturnal haemoglobinuria red cells by serum and cobra factor. Br J Haematol (1972) 1.10
Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol (1999) 1.09
Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d. J Immunol (1983) 1.09
gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4). Eur J Immunol (1985) 1.05
Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement (1987) 1.05
Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18). J Immunol (1991) 1.04
Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G. J Clin Invest (1978) 1.03
Hemorrhagic thrombocythemia; control of postsplenectomy thrombocytosis with melphalan. Blood (1970) 1.03
Surface markers of complement receptor lymphocytes. J Clin Invest (1978) 1.03
Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18). J Immunol (1999) 1.01
Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres. J Immunol (1982) 0.99
Felty's syndrome without splenomegaly. Am J Med (1979) 0.94
CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents. J Clin Immunol (1993) 0.93
Home as a place to die. Am J Nurs (1980) 0.93
Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Clin Exp Immunol (1999) 0.92
Surface markers of B and T cells. Recent technical developments reveal a heterogeneity of lymphocyte subpopulations. Arch Pathol Lab Med (1977) 0.92
Sudden death during doxorubicin administration. Cancer (1979) 0.92
Complement-dependent immune adherence measured with human granulocytes: changes in the antigenic nature of red cell-bound C3 produced by incubation in human serum. Clin Immunol Immunopathol (1973) 0.91
Phagocytosis by human monocyte-derived macrophages. Independent function of receptors for C3b (CR1) and iC3b (CR3). Complement (1984) 0.91
Clinical and laboratory features of patients with an inherited deficiency of neutrophil membrane complement receptor type 3 (CR3) and the related membrane antigens LFA-1 and p150,95. J Clin Immunol (1986) 0.90
Novel enzymatic and immunological responses to oligonucleotides. Toxicol Lett (1995) 0.90
Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3. J Immunol (1993) 0.89
Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement (1987) 0.88
Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease. N Engl J Med (1987) 0.88
Membrane receptors of mouse leukocytes. I. Two types of complement receptors for different regions of C3. J Immunol (1978) 0.87
Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). J Immunol (1997) 0.87
Transient acquired factor X deficiency associated with pneumonia. N Y State J Med (1984) 0.86
Immunologic mechanisms of hemolysis in autoimmune hemolytic anemia. Pathobiol Annu (1978) 0.86
Recurrent thrombocytopenia following idiopathic thrombocytopenic purpura. The importance of platelet-bound IgG in establishing cause. Arch Intern Med (1980) 0.86
Phorbol ester induces transient focal concentrations of functional, newly expressed CR3 in neutrophils at sites of specific granule exocytosis. Eur J Cell Biol (1991) 0.85
Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele. J Thorac Cardiovasc Surg (1997) 0.84
A mixed population of immature and mature leucocytes in umbilical cord blood results in a reduced expression and function of CR3 (CD11b/CD18). Clin Exp Immunol (1998) 0.83
Autoimmune granulocytopenia. Annu Rev Med (1980) 0.82
I and i antigens on normal and leukemic leukocytes. Cancer (1978) 0.82
Felty's syndrome: effects of splenectomy upon granulocyte count and granulocyte-associated IgG. Ann Intern Med (1981) 0.81
Relative risk of adolescent drug abuse: Part I. Socio-demographic and interpersonal variables. Bull Narc (1981) 0.81
Effect of heparin on complement activation and lysis of paroxysmal nocturnal hemoglobinuria (PNH) red cells. Blood (1977) 0.80
Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol (1997) 0.80
Replication of type I herpes simplex virus in primary cultures of hairy cell leukemic leukocytes. Am J Pathol (1978) 0.80
Endogenous carbon monoxide production measured by gas-phase analysis: an estimation of heme catabolic rate. J Lab Clin Med (1971) 0.80
Cardiac amyloidoma with IgM-kappa gammopathy. Arch Pathol Lab Med (1994) 0.80
Antibodies to granulocyte precursors in selective myeloid hypoplasia and other suspected autoimmune neutropenias: use of HL-60 cells as targets. Blood (1987) 0.80
Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies. Transfusion (1991) 0.79
Isolation and purification of C3 from human plasma. Curr Protoc Immunol (2001) 0.79
Activation of human complement by immunoglobulin G antigranulocyte antibody. J Clin Invest (1982) 0.79
Alpha-interferon for severe cold agglutinin disease. Ann Intern Med (1989) 0.79
Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia. Am J Med (1991) 0.79
Evaluating the superior vena cava syndrome. JAMA (1981) 0.79